IceCure Medical Ltd (ICCM)

NasdaqCM: ICCM · 실시간 가격 · USD

3.00

+0.00 (0.00%)

종가 기준: Aug 18, 2026, 8:00 PM

0.00% (1D)

데이터 없음

매수호가	2.16
시가총액	8.91M
매출 (ttm)	3.95M
순이익 (ttm)	-16.88M
베타	0.47
EPS (ttm)	-6.24
P/E (ttm)	n/a
선행 P/E	-0.79
P/B (ttm)	0.75
P/S (ttm)	2.26
Earnings Date	Aug 12, 2026

매도호가	3.96
거래량	12,623
평균 거래량 (20일)	3,337,380
시가	3.04
전일 종가	3.00
일중 범위	3.00 - 3.09
52주 범위	2.12 - 42.00
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ICCM 소개

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needle...

[더 보기]

산업 Medical Devices

섹터 Healthcare

IPO 일자 Aug 26, 2021

직원 수 67

상장 거래소 NasdaqCM

티커 ICCM

웹사이트 https://www.icecure-medical.com

전체 기업 정보

재무 실적

2025년 IceCure Medical Ltd의 매출은 3.38M로, 전년 3.29M 대비 2.67% 증가했습니다. 순이익은 -15.06M로, -1.7% 감소했습니다.

재무제표

어닝 서프라이즈

IceCure Medical Ltd가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $911K 예상치 하회 $0, 및 25.66% 전년 대비 성장.

EPS -1.37 예상치 하회 0.00, 및 23.89% 전년 대비 성장.

뉴스

6일 전 · Moby

IceCure Medical Ltd Q2 2026 Earnings Call Summary

Moby summary of IceCure Medical Ltd's Q2 2026 earnings call

1주 전 · Zacks

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates

Establishment Labs (ESTA) delivered earnings and revenue surprises of -14.71% and +3.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2개월 전 · Stocktwits

ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems.

3개월 전 · GuruFocus.com

Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ...

Icecure Medical Ltd (ICCM) reports a 26% revenue increase, driven by significant sales growth in North America and strategic FDA clearances.

3개월 전 · Moby

IceCure Medical Ltd Q1 2026 Earnings Call Summary

Moby summary of IceCure Medical Ltd's Q1 2026 earnings call

2 페이지 중 1

IceCure Medical Ltd (ICCM)

ICCM 소개